AIM ImmunoTech, Inc. - נכסים נקיים למניה בודדת AIM

High R&D costs during immunomodulator trials limit business scaling by increasing unit expenses, yet the unique drug Ampligen provides AIM ImmunoTech (AIM) with strong pricing power due to inelastic demand. The current book value per share on this chart confirms this basis, where the metric value stands at 0.27. Simultaneously, the company is implementing ESG standards by investing in energy-efficient biomaterial storage and the safe disposal of chemicals.

AIM ImmunoTech's bet on a full outsource model for drug development minimizes capital expenditures, which is directly reflected in the book value per share. This indicator is calculated as the difference between all company assets and liabilities divided by the number of shares, allowing investors to assess the actual remaining capital per share regardless of market speculation and emotional price volatility.